滚动资讯
CellAccelerating discovery of cancer causes for prevention in the era of rising early-onset cancersCellUbiquitin Ligase COP1 Suppresses Neuroinflammation by Degrading c/EBPβ in MicrogliaFierceBiotechJeito hails $1.2B as 'largest raise ever' for independent biopharma-focused European fundFierceBiotechOrbiMed’s Sidewinder slides toward clinic with $137M series B for antibody-drug conjugatesAgilentAgilent Technologies and BaseSolve Informatics Announce Co-Marketing Agreement to Deliver An Integrated NGS Workflow in the United States - TheWire.inPharmaVoiceWomen have awaited a revolution in menopause. It hasn’t arrived.Endpoints NewsADC biotech Sidewinder collects $137M for bispecific approachEndpoints NewsInsmed shelves Brinsupri in skin disease after mid-stage flopThermo FisherLatest Life Science Job at Thermo Fisher Scientific | Apply Before It Closes - biotecnika.org10x Genomics BlogWhy 10x Genomics Stock Is Surging Today - TipRanksFierceBiotechWith 3 acquisitions to digest, Gilead shifts focus from M&A to pipeline that has 'never been stronger'Endpoints NewsEuropean VC Jeito gets $1.2B to help private biotechs control their 'destiny'
Illumina 2026年3月10日

Illumina股票为何有望延续44%反弹势头至2026年——深度解析

Illumina股票为何有望延续44%反弹势头至2026年——深度解析

原文
暂时没有全文，请查看原始来源。

目录

59 全部